+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Biologics Contract Manufacturing Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2031 - By Product, Technology, Grade, Application, End-user, Region: (North America, Europe, Asia Pacific, Latin America and Middle East and Africa)- Product Image
Biologics Contract Manufacturing Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2031 - By Product, Technology, Grade, Application, End-user, Region: (North America, Europe, Asia Pacific, Latin America and Middle East and Africa)- Product Image
New

Biologics Contract Manufacturing Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2031 - By Product, Technology, Grade, Application, End-user, Region: (North America, Europe, Asia Pacific, Latin America and Middle East and Africa)

  • PDF Icon

    Report

  • 185 Pages
  • November 2024
  • Region: Global
  • Fairfield Market Research
  • ID: 5916057
Description Jump to:
The global biologics contract manufacturing market is poised for significant growth, with worldwide revenue expected to grow from USD 16.01 billion in 2024 to a substantial USD 36.3 billion by 2031. Projected to expand at a CAGR of 12.4%, this market reflects an increased demand for novel biologic and biosimilar products, especially as companies embrace contract manufacturing to streamline R&D and commercialization processes.

The biologics contract manufacturing market is driven by the expansion of the biopharmaceutical contract manufacturing organization (CMO) sector. Consolidation efforts are underway, with market participants adopting inorganic growth strategies and developing end-to-end integrated solutions that offer clients comprehensive services. Biopharmaceutical CMOs with advanced technological capabilities are uniquely positioned to capitalize on this burgeoning market, bolstered by rapid scientific advancements in the field.

Drivers of Market Growth

1. Growing Demand for Biologics and Biosimilars: The need for innovative biologics and biosimilars is expanding, spurring demand for contract manufacturing services.

2. R&D Outsourcing: Companies increasingly rely on CMOs and CDMOs (contract development and manufacturing organizations) to optimize R&D expenditures, enhancing operational efficiency.

3. Scientific and Technological Advancements: Innovations in biopharmaceutical manufacturing, such as single-use bioreactors and cell & gene therapy capabilities, are propelling market growth. Notable examples include Lonza Group AG’s acquisition of a Shire plc facility, enhancing their mammalian manufacturing operations, and AGC Biologics’ acquisition of Molecular Medicine S.p.A. to strengthen its gene therapy capabilities.

Business Opportunities

The CDMO business model is evolving to support high potency drug development and biopharmaceuticals, offering a range of product options that drive competitive differentiation. By outsourcing stages of clinical development to strategic partners, companies can achieve greater efficiencies across the value chain. Furthermore, as CMOs and CDMOs optimize manufacturing technologies, they are also creating opportunities for long-term profitability through cost-effective and scalable solutions.

Region Analysis

  • United States: In North America, the U.S. holds a leading position, capturing approximately 89.9% of the market in 2023. Strong pipelines for biologics, high venture capital investment in biotechnology R&D, and a growing presence of prominent manufacturers and research institutions contribute to the U.S. market's strength.
  • Germany: Holding around 33.7% of the European market share in 2023, Germany is emerging as a lucrative market. Increasing biopharmaceutical research and clinical trials drive demand, with many companies outsourcing their research activities to reduce costs.
  • China: China commands an 18.2% market share within East Asia, driven by collaborations between global and local firms. As pharmaceutical and biopharmaceutical companies increase their presence in China, they unlock opportunities for contract manufacturing growth over the forecast period.

Impact of Regulatory Dynamics

The biologics contract manufacturing market faces some challenges due to shifting regulatory policies, cGMP compliance requirements, and complex supply chain security issues in emerging countries. Entry barriers are high for small and medium enterprises (SMEs) due to substantial financial requirements. Additionally, many countries face a shortage of skilled professionals and adequate funding, slowing the development of a robust biotech industry similar to that in the U.S.

Competitive Analysis

Leading companies are focusing on expanding their service portfolios and establishing a presence in emerging markets to capitalize on growth potential. Major players in the biologics contract manufacturing market include.
  • BioXcellence (Boehringer Ingelheim)
  • Lonza Group AG
  • Samsung Biologics
  • Fujifilm Diosynth Biotechnologies
  • AbbVie CM (AbbVie Inc.)
  • WuXi Biologics (Cayman) Inc.
  • AGC Biologics
  • Patheon N.V. (Thermo Fisher Scientific Inc.)
  • Emergent BioSolutions Inc.
  • Ajinomoto Bio-Pharma
  • Avid Bioservices, Inc.
  • KBI Biopharma
  • Rentschler Biotechnologie GmbH
  • Merck KGaA
  • Catalent Inc.
  • Therapure Biopharma Inc.
  • Novasep
  • Abzena plc.
  • ProBioGen AG

Biologics Contract Manufacturing Market Segmentation

The biologics contract manufacturing market is segmented as follows:

Product:

  • Monoclonal Antibodies
  • Recombinant Proteins
  • Vaccines
  • Insulin
  • Interferons
  • Growth Factors
  • Others

Platform:

  • Mammalian
  • Microbial

Therapeutic Area:

  • Oncology
  • Autoimmune Disease
  • Metabolic Disease
  • Ophthalmology
  • Cardiovascular Disease
  • Infectious Disease
  • Neurology
  • Respiratory Disorder
  • Others

Application:

  • Commercial
  • Clinical

Region:

  • North America
  • Latin America
  • Europe
  • South Asia
  • East Asia
  • Oceania
  • Middle East & Africa


This product will be delivered within 1-3 business days.

Table of Contents

1. Executive Summary
1.1. Global Biologics Contract Manufacturing Market Snapshot
1.2. Future Projections
1.3. Key Market Trends
1.4. Regional Snapshot, by Value and Volume, 2024
1.5. Analyst Recommendations
2. Market Overview
2.1. Market Definitions and Segmentations
2.2. Market Dynamics
2.2.1. Drivers
2.2.2. Restraints
2.2.3. Market Opportunities
2.3. Value Chain Analysis
2.4. Porter’s Five Forces Analysis
2.5. COVID-19 Impact Analysis
2.5.1. Supply
2.5.2. Demand
2.6. Impact of Ukraine-Russia Conflict
2.7. Economic Overview
2.7.1. World Economic Projections
2.8. PESTLE Analysis
3. Price Analysis, 2018 - 2023
3.1. Global Average Price Analysis, by Product/ Platform, US$ Per Unit, 2018 - 2023
3.2. Prominent Factor Affecting Biologics Contract Manufacturing Prices
3.3. Global Average Price Analysis, by Region, US$ Per Unit
4. Global Biologics Contract Manufacturing Market Outlook, 2019-2031
4.1. Global Biologics Contract Manufacturing Market Outlook, by Product, Value (US$ Bn) and Volume (KL), 2019-2031
4.1.1. Key Highlights
4.1.1.1. Monoclonal Antibodies
4.1.1.2. Recombinant Proteins
4.1.1.3. Vaccines
4.1.1.4. Insulin
4.1.1.5. Interferons
4.1.1.6. Growth Factors
4.1.1.7. Others
4.2. Global Biologics Contract Manufacturing Market Outlook, by Platform, Value (US$ Bn) and Volume (KL), 2019-2031
4.2.1. Key Highlights
4.2.1.1. Mammalian
4.2.1.2. Microbial
4.3. Global Biologics Contract Manufacturing Market Outlook, by Therapeutic Area, Value (US$ Bn) and Volume (KL), 2019-2031
4.3.1. Key Highlights
4.3.1.1. Oncology
4.3.1.2. Autoimmune Disease
4.3.1.3. Metabolic Disease
4.3.1.4. Ophthalmology
4.3.1.5. Cardiovascular Disease
4.3.1.6. Infectious Disease
4.3.1.7. Neurology
4.3.1.8. Respiratory Disorder
4.3.1.9. Others
4.4. Global Biologics Contract Manufacturing Market Outlook, by Application, Value (US$ Bn) and Volume (KL), 2019-2031
4.4.1. Key Highlights
4.4.1.1. Commercial
4.4.1.2. Clinical
4.5. Global Biologics Contract Manufacturing Market Outlook, by Region, Value (US$ Bn) and Volume (KL), 2019-2031
4.5.1. Key Highlights
4.5.1.1. North America
4.5.1.2. Europe
4.5.1.3. Asia Pacific
4.5.1.4. Latin America
4.5.1.5. Middle East & Africa
5. North America Biologics Contract Manufacturing Market Outlook, 2019-2031
5.1. North America Biologics Contract Manufacturing Market Outlook, by Product, Value (US$ Bn) and Volume (KL), 2019-2031
5.1.1. Key Highlights
5.1.1.1. Monoclonal Antibodies
5.1.1.2. Recombinant Proteins
5.1.1.3. Vaccines
5.1.1.4. Insulin
5.1.1.5. Interferons
5.1.1.6. Growth Factors
5.1.1.7. Others
5.2. North America Biologics Contract Manufacturing Market Outlook, by Platform, Value (US$ Bn) and Volume (KL), 2019-2031
5.2.1. Key Highlights
5.2.1.1. Mammalian
5.2.1.2. Microbial
5.3. North America Biologics Contract Manufacturing Market Outlook, by Therapeutic Area, Value (US$ Bn) and Volume (KL), 2019-2031
5.3.1. Key Highlights
5.3.1.1. Oncology
5.3.1.2. Autoimmune Disease
5.3.1.3. Metabolic Disease
5.3.1.4. Ophthalmology
5.3.1.5. Cardiovascular Disease
5.3.1.6. Infectious Disease
5.3.1.7. Neurology
5.3.1.8. Respiratory Disorder
5.3.1.9. Others
5.4. North America Biologics Contract Manufacturing Market Outlook, by Application, Value (US$ Bn) and Volume (KL), 2019-2031
5.4.1. Key Highlights
5.4.1.1. Commercial
5.4.1.2. Clinical
5.5. North America Biologics Contract Manufacturing Market Outlook, by Country, Value (US$ Bn) and Volume (KL), 2019-2031
5.5.1. Key Highlights
5.5.1.1. U.S. Biologics Contract Manufacturing Market by Product, Value (US$ Bn) and Volume (KL), 2019-2031
5.5.1.2. U.S. Biologics Contract Manufacturing Market by Platform, Value (US$ Bn) and Volume (KL), 2019-2031
5.5.1.3. U.S. Biologics Contract Manufacturing Market by Therapeutic Area, Value (US$ Bn) and Volume (KL), 2019-2031
5.5.1.4. U.S. Biologics Contract Manufacturing Market by Application, Value (US$ Bn) and Volume (KL), 2019-2031
5.5.1.5. Canada Biologics Contract Manufacturing Market by Product, Value (US$ Bn) and Volume (KL), 2019-2031
5.5.1.6. Canada Biologics Contract Manufacturing Market by Platform, Value (US$ Bn) and Volume (KL), 2019-2031
5.5.1.7. Canada Biologics Contract Manufacturing Market by Therapeutic Area, Value (US$ Bn) and Volume (KL), 2019-2031
5.5.1.8. Canada Biologics Contract Manufacturing Market by Application, Value (US$ Bn) and Volume (KL), 2019-2031
5.5.2. BPS Analysis/Market Attractiveness Analysis
6. Europe Biologics Contract Manufacturing Market Outlook, 2019-2031
6.1. Europe Biologics Contract Manufacturing Market Outlook, by Product, Value (US$ Bn) and Volume (KL), 2019-2031
6.1.1. Key Highlights
6.1.1.1. Monoclonal Antibodies
6.1.1.2. Recombinant Proteins
6.1.1.3. Vaccines
6.1.1.4. Insulin
6.1.1.5. Interferons
6.1.1.6. Growth Factors
6.1.1.7. Others
6.2. Europe Biologics Contract Manufacturing Market Outlook, by Platform, Value (US$ Bn) and Volume (KL), 2019-2031
6.2.1. Key Highlights
6.2.1.1. Mammalian
6.2.1.2. Microbial
6.3. Europe Biologics Contract Manufacturing Market Outlook, by Therapeutic Area, Value (US$ Bn) and Volume (KL), 2019-2031
6.3.1. Key Highlights
6.3.1.1. Oncology
6.3.1.2. Autoimmune Disease
6.3.1.3. Metabolic Disease
6.3.1.4. Ophthalmology
6.3.1.5. Cardiovascular Disease
6.3.1.6. Infectious Disease
6.3.1.7. Neurology
6.3.1.8. Respiratory Disorder
6.3.1.9. Others
6.4. Europe Biologics Contract Manufacturing Market Outlook, by Application, Value (US$ Bn) and Volume (KL), 2019-2031
6.4.1. Key Highlights
6.4.1.1. Commercial
6.4.1.2. Clinical
6.5. Europe Biologics Contract Manufacturing Market Outlook, by Country, Value (US$ Bn) and Volume (KL), 2019-2031
6.5.1. Key Highlights
6.5.1.1. Germany Biologics Contract Manufacturing Market by Product, Value (US$ Bn) and Volume (KL), 2019-2031
6.5.1.2. Germany Biologics Contract Manufacturing Market by Platform, Value (US$ Bn) and Volume (KL), 2019-2031
6.5.1.3. Germany Biologics Contract Manufacturing Market by Therapeutic Area, Value (US$ Bn) and Volume (KL), 2019-2031
6.5.1.4. Germany Biologics Contract Manufacturing Market by Application, Value (US$ Bn) and Volume (KL), 2019-2031
6.5.1.5. U.K. Biologics Contract Manufacturing Market by Product, Value (US$ Bn) and Volume (KL), 2019-2031
6.5.1.6. U.K. Biologics Contract Manufacturing Market by Platform, Value (US$ Bn) and Volume (KL), 2019-2031
6.5.1.7. U.K. Biologics Contract Manufacturing Market by Therapeutic Area, Value (US$ Bn) and Volume (KL), 2019-2031
6.5.1.8. U.K. Biologics Contract Manufacturing Market by Application, Value (US$ Bn) and Volume (KL), 2019-2031
6.5.1.9. France Biologics Contract Manufacturing Market by Product, Value (US$ Bn) and Volume (KL), 2019-2031
6.5.1.10. France Biologics Contract Manufacturing Market by Platform, Value (US$ Bn) and Volume (KL), 2019-2031
6.5.1.11. France Biologics Contract Manufacturing Market by Therapeutic Area, Value (US$ Bn) and Volume (KL), 2019-2031
6.5.1.12. France Biologics Contract Manufacturing Market by Application, Value (US$ Bn) and Volume (KL), 2019-2031
6.5.1.13. Italy Biologics Contract Manufacturing Market by Product, Value (US$ Bn) and Volume (KL), 2019-2031
6.5.1.14. Italy Biologics Contract Manufacturing Market by Platform, Value (US$ Bn) and Volume (KL), 2019-2031
6.5.1.15. Italy Biologics Contract Manufacturing Market by Therapeutic Area, Value (US$ Bn) and Volume (KL), 2019-2031
6.5.1.16. Italy Biologics Contract Manufacturing Market by Application, Value (US$ Bn) and Volume (KL), 2019-2031
6.5.1.17. Turkey Biologics Contract Manufacturing Market by Product, Value (US$ Bn) and Volume (KL), 2019-2031
6.5.1.18. Turkey Biologics Contract Manufacturing Market by Platform, Value (US$ Bn) and Volume (KL), 2019-2031
6.5.1.19. Turkey Biologics Contract Manufacturing Market by Therapeutic Area, Value (US$ Bn) and Volume (KL), 2019-2031
6.5.1.20. Turkey Biologics Contract Manufacturing Market by Application, Value (US$ Bn) and Volume (KL), 2019-2031
6.5.1.21. Russia Biologics Contract Manufacturing Market by Product, Value (US$ Bn) and Volume (KL), 2019-2031
6.5.1.22. Russia Biologics Contract Manufacturing Market by Platform, Value (US$ Bn) and Volume (KL), 2019-2031
6.5.1.23. Russia Biologics Contract Manufacturing Market by Therapeutic Area, Value (US$ Bn) and Volume (KL), 2019-2031
6.5.1.24. Russia Biologics Contract Manufacturing Market by Application, Value (US$ Bn) and Volume (KL), 2019-2031
6.5.1.25. Rest of Europe Biologics Contract Manufacturing Market by Product, Value (US$ Bn) and Volume (KL), 2019-2031
6.5.1.26. Rest of Europe Biologics Contract Manufacturing Market by Platform, Value (US$ Bn) and Volume (KL), 2019-2031
6.5.1.27. Rest of Europe Biologics Contract Manufacturing Market by Therapeutic Area, Value (US$ Bn) and Volume (KL), 2019-2031
6.5.1.28. Rest of Europe Biologics Contract Manufacturing Market by Application, Value (US$ Bn) and Volume (KL), 2019-2031
6.5.2. BPS Analysis/Market Attractiveness Analysis
7. Asia Pacific Biologics Contract Manufacturing Market Outlook, 2019-2031
7.1. Asia Pacific Biologics Contract Manufacturing Market Outlook, by Product, Value (US$ Bn) and Volume (KL), 2019-2031
7.1.1. Key Highlights
7.1.1.1. Monoclonal Antibodies
7.1.1.2. Recombinant Proteins
7.1.1.3. Vaccines
7.1.1.4. Insulin
7.1.1.5. Interferons
7.1.1.6. Growth Factors
7.1.1.7. Others
7.2. Asia Pacific Biologics Contract Manufacturing Market Outlook, by Platform, Value (US$ Bn) and Volume (KL), 2019-2031
7.2.1. Key Highlights
7.2.1.1. Mammalian
7.2.1.2. Microbial
7.3. Asia Pacific Biologics Contract Manufacturing Market Outlook, by Therapeutic Area, Value (US$ Bn) and Volume (KL), 2019-2031
7.3.1. Key Highlights
7.3.1.1. Oncology
7.3.1.2. Autoimmune Disease
7.3.1.3. Metabolic Disease
7.3.1.4. Ophthalmology
7.3.1.5. Cardiovascular Disease
7.3.1.6. Infectious Disease
7.3.1.7. Neurology
7.3.1.8. Respiratory Disorder
7.3.1.9. Others
7.4. Asia Pacific Biologics Contract Manufacturing Market Outlook, by Application, Value (US$ Bn) and Volume (KL), 2019-2031
7.4.1. Key Highlights
7.4.1.1. Commercial
7.4.1.2. Clinical
7.5. Asia Pacific Biologics Contract Manufacturing Market Outlook, by Country, Value (US$ Bn) and Volume (KL), 2019-2031
7.5.1. Key Highlights
7.5.1.1. China Biologics Contract Manufacturing Market by Product, Value (US$ Bn) and Volume (KL), 2019-2031
7.5.1.2. China Biologics Contract Manufacturing Market by Platform, Value (US$ Bn) and Volume (KL), 2019-2031
7.5.1.3. China Biologics Contract Manufacturing Market by Therapeutic Area, Value (US$ Bn) and Volume (KL), 2019-2031
7.5.1.4. China Biologics Contract Manufacturing Market by Application, Value (US$ Bn) and Volume (KL), 2019-2031
7.5.1.5. Japan Biologics Contract Manufacturing Market by Product, Value (US$ Bn) and Volume (KL), 2019-2031
7.5.1.6. Japan Biologics Contract Manufacturing Market by Platform, Value (US$ Bn) and Volume (KL), 2019-2031
7.5.1.7. Japan Biologics Contract Manufacturing Market by Therapeutic Area, Value (US$ Bn) and Volume (KL), 2019-2031
7.5.1.8. Japan Biologics Contract Manufacturing Market by Application, Value (US$ Bn) and Volume (KL), 2019-2031
7.5.1.9. South Korea Biologics Contract Manufacturing Market by Product, Value (US$ Bn) and Volume (KL), 2019-2031
7.5.1.10. South Korea Biologics Contract Manufacturing Market by Platform, Value (US$ Bn) and Volume (KL), 2019-2031
7.5.1.11. South Korea Biologics Contract Manufacturing Market by Therapeutic Area, Value (US$ Bn) and Volume (KL), 2019-2031
7.5.1.12. South Korea Biologics Contract Manufacturing Market by Application, Value (US$ Bn) and Volume (KL), 2019-2031
7.5.1.13. India Biologics Contract Manufacturing Market by Product, Value (US$ Bn) and Volume (KL), 2019-2031
7.5.1.14. India Biologics Contract Manufacturing Market by Platform, Value (US$ Bn) and Volume (KL), 2019-2031
7.5.1.15. India Biologics Contract Manufacturing Market by Therapeutic Area, Value (US$ Bn) and Volume (KL), 2019-2031
7.5.1.16. India Biologics Contract Manufacturing Market by Application, Value (US$ Bn) and Volume (KL), 2019-2031
7.5.1.17. Southeast Asia Biologics Contract Manufacturing Market by Product, Value (US$ Bn) and Volume (KL), 2019-2031
7.5.1.18. Southeast Asia Biologics Contract Manufacturing Market by Platform, Value (US$ Bn) and Volume (KL), 2019-2031
7.5.1.19. Southeast Asia Biologics Contract Manufacturing Market by Therapeutic Area, Value (US$ Bn) and Volume (KL), 2019-2031
7.5.1.20. Southeast Asia Biologics Contract Manufacturing Market by Application, Value (US$ Bn) and Volume (KL), 2019-2031
7.5.1.21. Rest of Asia Pacific Biologics Contract Manufacturing Market by Product, Value (US$ Bn) and Volume (KL), 2019-2031
7.5.1.22. Rest of Asia Pacific Biologics Contract Manufacturing Market by Platform, Value (US$ Bn) and Volume (KL), 2019-2031
7.5.1.23. Rest of Asia Pacific Biologics Contract Manufacturing Market by Therapeutic Area, Value (US$ Bn) and Volume (KL), 2019-2031
7.5.1.24. Rest of Asia Pacific Biologics Contract Manufacturing Market by Application, Value (US$ Bn) and Volume (KL), 2019-2031
7.5.2. BPS Analysis/Market Attractiveness Analysis
8. Latin America Biologics Contract Manufacturing Market Outlook, 2019-2031
8.1. Latin America Biologics Contract Manufacturing Market Outlook, by Product, Value (US$ Bn) and Volume (KL), 2019-2031
8.1.1. Key Highlights
8.1.1.1. Monoclonal Antibodies
8.1.1.2. Recombinant Proteins
8.1.1.3. Vaccines
8.1.1.4. Insulin
8.1.1.5. Interferons
8.1.1.6. Growth Factors
8.1.1.7. Others
8.2. Latin America Biologics Contract Manufacturing Market Outlook, by Platform, Value (US$ Bn) and Volume (KL), 2019-2031
8.2.1. Key Highlights
8.2.1.1. Mammalian
8.2.1.2. Microbial
8.3. Latin America Biologics Contract Manufacturing Market Outlook, by Therapeutic Area, Value (US$ Bn) and Volume (KL), 2019-2031
8.3.1. Key Highlights
8.3.1.1. Oncology
8.3.1.2. Autoimmune Disease
8.3.1.3. Metabolic Disease
8.3.1.4. Ophthalmology
8.3.1.5. Cardiovascular Disease
8.3.1.6. Infectious Disease
8.3.1.7. Neurology
8.3.1.8. Respiratory Disorder
8.3.1.9. Others
8.4. Latin America Biologics Contract Manufacturing Market Outlook, by Application, Value (US$ Bn) and Volume (KL), 2019-2031
8.4.1. Key Highlights
8.4.1.1. Commercial
8.4.1.2. Clinical
8.5. Latin America Biologics Contract Manufacturing Market Outlook, by Country, Value (US$ Bn) and Volume (KL), 2019-2031
8.5.1. Key Highlights
8.5.1.1. Brazil Biologics Contract Manufacturing Market by Product, Value (US$ Bn) and Volume (KL), 2019-2031
8.5.1.2. Brazil Biologics Contract Manufacturing Market by Platform, Value (US$ Bn) and Volume (KL), 2019-2031
8.5.1.3. Brazil Biologics Contract Manufacturing Market by Therapeutic Area, Value (US$ Bn) and Volume (KL), 2019-2031
8.5.1.4. Brazil Biologics Contract Manufacturing Market by Application, Value (US$ Bn) and Volume (KL), 2019-2031
8.5.1.5. Mexico Biologics Contract Manufacturing Market by Product, Value (US$ Bn) and Volume (KL), 2019-2031
8.5.1.6. Mexico Biologics Contract Manufacturing Market by Platform, Value (US$ Bn) and Volume (KL), 2019-2031
8.5.1.7. Mexico Biologics Contract Manufacturing Market by Therapeutic Area, Value (US$ Bn) and Volume (KL), 2019-2031
8.5.1.8. Mexico Biologics Contract Manufacturing Market by Application, Value (US$ Bn) and Volume (KL), 2019-2031
8.5.1.9. Argentina Biologics Contract Manufacturing Market by Product, Value (US$ Bn) and Volume (KL), 2019-2031
8.5.1.10. Argentina Biologics Contract Manufacturing Market by Platform, Value (US$ Bn) and Volume (KL), 2019-2031
8.5.1.11. Argentina Biologics Contract Manufacturing Market by Therapeutic Area, Value (US$ Bn) and Volume (KL), 2019-2031
8.5.1.12. Argentina Biologics Contract Manufacturing Market by Application, Value (US$ Bn) and Volume (KL), 2019-2031
8.5.1.13. Rest of Latin America Biologics Contract Manufacturing Market by Product, Value (US$ Bn) and Volume (KL), 2019-2031
8.5.1.14. Rest of Latin America Biologics Contract Manufacturing Market by Platform, Value (US$ Bn) and Volume (KL), 2019-2031
8.5.1.15. Rest of Latin America Biologics Contract Manufacturing Market by Therapeutic Area, Value (US$ Bn) and Volume (KL), 2019-2031
8.5.1.16. Rest of Latin America Biologics Contract Manufacturing Market by Application, Value (US$ Bn) and Volume (KL), 2019-2031
8.5.2. BPS Analysis/Market Attractiveness Analysis
9. Middle East & Africa Biologics Contract Manufacturing Market Outlook, 2019-2031
9.1. Middle East & Africa Biologics Contract Manufacturing Market Outlook, by Product, Value (US$ Bn) and Volume (KL), 2019-2031
9.1.1. Key Highlights
9.1.1.1. Monoclonal Antibodies
9.1.1.2. Recombinant Proteins
9.1.1.3. Vaccines
9.1.1.4. Insulin
9.1.1.5. Interferons
9.1.1.6. Growth Factors
9.1.1.7. Others
9.2. Middle East & Africa Biologics Contract Manufacturing Market Outlook, by Platform, Value (US$ Bn) and Volume (KL), 2019-2031
9.2.1. Key Highlights
9.2.1.1. Mammalian
9.2.1.2. Microbial
9.3. Middle East & Africa Biologics Contract Manufacturing Market Outlook, by Therapeutic Area, Value (US$ Bn) and Volume (KL), 2019-2031
9.3.1. Key Highlights
9.3.1.1. Oncology
9.3.1.2. Autoimmune Disease
9.3.1.3. Metabolic Disease
9.3.1.4. Ophthalmology
9.3.1.5. Cardiovascular Disease
9.3.1.6. Infectious Disease
9.3.1.7. Neurology
9.3.1.8. Respiratory Disorder
9.3.1.9. Others
9.4. Middle East & Africa Biologics Contract Manufacturing Market Outlook, by Application, Value (US$ Bn) and Volume (KL), 2019-2031
9.4.1. Key Highlights
9.4.1.1. Commercial
9.4.1.2. Clinical
9.5. Middle East & Africa Biologics Contract Manufacturing Market Outlook, by Country, Value (US$ Bn) and Volume (KL), 2019-2031
9.5.1. Key Highlights
9.5.1.1. GCC Biologics Contract Manufacturing Market by Product, Value (US$ Bn) and Volume (KL), 2019-2031
9.5.1.2. GCC Biologics Contract Manufacturing Market by Platform, Value (US$ Bn) and Volume (KL), 2019-2031
9.5.1.3. GCC Biologics Contract Manufacturing Market by Therapeutic Area, Value (US$ Bn) and Volume (KL), 2019-2031
9.5.1.4. GCC Biologics Contract Manufacturing Market by Application, Value (US$ Bn) and Volume (KL), 2019-2031
9.5.1.5. South Africa Biologics Contract Manufacturing Market by Product, Value (US$ Bn) and Volume (KL), 2019-2031
9.5.1.6. South Africa Biologics Contract Manufacturing Market by Platform, Value (US$ Bn) and Volume (KL), 2019-2031
9.5.1.7. South Africa Biologics Contract Manufacturing Market by Therapeutic Area, Value (US$ Bn) and Volume (KL), 2019-2031
9.5.1.8. South Africa Biologics Contract Manufacturing Market by Application, Value (US$ Bn) and Volume (KL), 2019-2031
9.5.1.9. Egypt Biologics Contract Manufacturing Market by Product, Value (US$ Bn) and Volume (KL), 2019-2031
9.5.1.10. Egypt Biologics Contract Manufacturing Market by Platform, Value (US$ Bn) and Volume (KL), 2019-2031
9.5.1.11. Egypt Biologics Contract Manufacturing Market by Therapeutic Area, Value (US$ Bn) and Volume (KL), 2019-2031
9.5.1.12. Egypt Biologics Contract Manufacturing Market by Application, Value (US$ Bn) and Volume (KL), 2019-2031
9.5.1.13. Nigeria Biologics Contract Manufacturing Market by Product, Value (US$ Bn) and Volume (KL), 2019-2031
9.5.1.14. Nigeria Biologics Contract Manufacturing Market by Platform, Value (US$ Bn) and Volume (KL), 2019-2031
9.5.1.15. Nigeria Biologics Contract Manufacturing Market by Therapeutic Area, Value (US$ Bn) and Volume (KL), 2019-2031
9.5.1.16. Nigeria Biologics Contract Manufacturing Market by Application, Value (US$ Bn) and Volume (KL), 2019-2031
9.5.1.17. Rest of Middle East & Africa Biologics Contract Manufacturing Market by Product, Value (US$ Bn) and Volume (KL), 2019-2031
9.5.1.18. Rest of Middle East & Africa Biologics Contract Manufacturing Market by Platform, Value (US$ Bn) and Volume (KL), 2019-2031
9.5.1.19. Rest of Middle East & Africa Biologics Contract Manufacturing Market by Therapeutic Area, Value (US$ Bn) and Volume (KL), 2019-2031
9.5.1.20. Rest of Middle East & Africa Biologics Contract Manufacturing Market by Application, Value (US$ Bn) and Volume (KL), 2019-2031
9.5.2. BPS Analysis/Market Attractiveness Analysis
10. Competitive Landscape
10.1. Product vs Platform Heatmap
10.2. Competitive Dashboard
10.3. Company Profiles
10.3.1. BioXcellence (Boehringer Ingelheim)
10.3.1.1. Company Overview
10.3.1.2. Product Portfolio
10.3.1.3. Financial Overview
10.3.1.4. Business Strategies and Development
10.3.2. Lonza Group AG
10.3.2.1. Company Overview
10.3.2.2. Product Portfolio
10.3.2.3. Financial Overview
10.3.2.4. Business Strategies and Development
10.3.3. Samsung Biologics
10.3.3.1. Company Overview
10.3.3.2. Product Portfolio
10.3.3.3. Financial Overview
10.3.3.4. Business Strategies and Development
10.3.4. Fujifilm Diosynth Biotechnologies
10.3.4.1. Company Overview
10.3.4.2. Product Portfolio
10.3.4.3. Financial Overview
10.3.4.4. Business Strategies and Development
10.3.5. AbbVie CM (AbbVie Inc.)
10.3.5.1. Company Overview
10.3.5.2. Product Portfolio
10.3.5.3. Financial Overview
10.3.5.4. Business Strategies and Development
10.3.6. WuXi Biologics (Cayman) Inc.
10.3.6.1. Company Overview
10.3.6.2. Product Portfolio
10.3.6.3. Financial Overview
10.3.6.4. Business Strategies and Development
10.3.7. AGC Biologics
10.3.7.1. Company Overview
10.3.7.2. Product Portfolio
10.3.7.3. Financial Overview
10.3.7.4. Business Strategies and Development
10.3.8. Patheon N.V. (Thermo Fisher Scientific Inc.)
10.3.8.1. Company Overview
10.3.8.2. Product Portfolio
10.3.8.3. Financial Overview
10.3.8.4. Business Strategies and Development
10.3.9. Emergent BioSolutions Inc.
10.3.9.1. Company Overview
10.3.9.2. Product Portfolio
10.3.9.3. Financial Overview
10.3.9.4. Business Strategies and Development
10.3.10. Ajinomoto Bio-Pharma
10.3.10.1. Company Overview
10.3.10.2. Product Portfolio
10.3.10.3. Financial Overview
10.3.10.4. Business Strategies and Development
10.3.11. Avid Bioservices, Inc.
10.3.11.1. Company Overview
10.3.11.2. Product Portfolio
10.3.11.3. Financial Overview
10.3.11.4. Business Strategies and Development
10.3.12. KBI Biopharma
10.3.12.1. Company Overview
10.3.12.2. Product Portfolio
10.3.12.3. Financial Overview
10.3.12.4. Business Strategies and Development
10.3.13. Rentschler Biotechnologie GmbH
10.3.13.1. Company Overview
10.3.13.2. Product Portfolio
10.3.13.3. Financial Overview
10.3.13.4. Business Strategies and Development
10.3.14. Merck KGaA
10.3.14.1. Company Overview
10.3.14.2. Product Portfolio
10.3.14.3. Financial Overview
10.3.14.4. Business Strategies and Development
10.3.15. Catalent Inc.
10.3.15.1. Company Overview
10.3.15.2. Product Portfolio
10.3.15.3. Financial Overview
10.3.15.4. Business Strategies and Development
10.3.16. Therapure Biopharma Inc.
10.3.16.1. Company Overview
10.3.16.2. Product Portfolio
10.3.16.3. Financial Overview
10.3.16.4. Business Strategies and Development
10.3.17. Novasep
10.3.17.1. Company Overview
10.3.17.2. Product Portfolio
10.3.17.3. Financial Overview
10.3.17.4. Business Strategies and Development
10.3.18. Abzena plc.
10.3.18.1. Company Overview
10.3.18.2. Product Portfolio
10.3.18.3. Financial Overview
10.3.18.4. Business Strategies and Development
10.3.19. ProBioGen AG
10.3.19.1. Company Overview
10.3.19.2. Product Portfolio
10.3.19.3. Financial Overview
10.3.19.4. Business Strategies and Development
11. Appendix
11.1. Research Methodology
11.2. Report Assumptions
11.3. Acronyms and Abbreviations

Companies Mentioned

  • Samsung Biologics
  • BioXcellence (Boehringer Ingelheim)
  • Lonza Group AG
  • Fujifilm Diosynth Biotechnologies
  • AbbVie CM (AbbVie Inc.)
  • WuXi Biologics (Cayman) Inc.
  • AGC Biologics
  • Patheon N.V. (Thermo Fisher Scientific Inc.)
  • Emergent BioSolutions Inc.
  • Ajinomoto Bio-Pharma
  • Avid Bioservices, Inc.
  • KBI Biopharma
  • Rentschler Biotechnologie GmbH
  • Merck KGaA
  • Catalent Inc.
  • Therapure Biopharma Inc.
  • Novasep
  • Abzena plc.
  • ProBioGen AG

Methodology

Loading
LOADING...

Related Topics

Related Reports

Biologics Safety Testing Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2031 - By Product, Technology, Grade, Application, End-user, Region: (North America, Europe, Asia Pacific, Latin America and Middle East and Africa) - Product Image

Biologics Safety Testing Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2031 - By Product, Technology, Grade, Application, End-user, Region: (North America, Europe, Asia Pacific, Latin America and Middle East and Africa)

  • Report
  • 170 Pages
  • Global
From
Dermatology Biologics Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2031 - By Product, Technology, Grade, Application, End-user, Region: (North America, Europe, Asia Pacific, Latin America and Middle East and Africa) - Product Image

Dermatology Biologics Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2031 - By Product, Technology, Grade, Application, End-user, Region: (North America, Europe, Asia Pacific, Latin America and Middle East and Africa)

  • Report
  • 250 Pages
  • Global
From
Biologics Market Size and Forecast 2021 - 2031, Global and Regional Share, Trend and Growth Opportunity Analysis Report Coverage: By Product, Application, Source, Manufacturing and Geography - Product Image

Biologics Market Size and Forecast 2021 - 2031, Global and Regional Share, Trend and Growth Opportunity Analysis Report Coverage: By Product, Application, Source, Manufacturing and Geography

  • Report
  • 200 Pages
  • Global
From
Global Biologics Contract Manufacturing (Biopharma CDMO/Biopharma CMO/Biologics Manufacturing) Market 2022-2035 by Type of Service(s) Offered, Type of Biologic Manufactured, Type of Expression System Used, Scale of Operation, Company Size, and Key Geographical Regions - Product Image

Global Biologics Contract Manufacturing (Biopharma CDMO/Biopharma CMO/Biologics Manufacturing) Market 2022-2035 by Type of Service(s) Offered, Type of Biologic Manufactured, Type of Expression System Used, Scale of Operation, Company Size, and Key Geographical Regions

  • Report
  • 799 Pages
  • Global
From
Biologics Contract Manufacturing Market by Product, Platform, Therapeutic Area, Scale of Operation - Global Forecast 2025-2030 - Product Image

Biologics Contract Manufacturing Market by Product, Platform, Therapeutic Area, Scale of Operation - Global Forecast 2025-2030

  • Report
  • 182 Pages
  • Global
From
Copyright © 2002-2024 Research and Markets. All Rights Reserved.